Skip to main content
. 2012 Jan 31;34(1):30–38. doi: 10.1093/eurheartj/ehr504

Figure 4.

Figure 4

Effect (mean ± SE) of ferric carboxymaltose on (A) Kansas City Cardiomyopathy Questionnaire clinical summary score (CSS; integrates total symptom score and physical limitation domain) and (B) Kansas City Cardiomyopathy Questionnaire quality of life domain among anaemic and non-anaemic subjects in the FAIR-HF study population.